Nearly 2 to 1 patients prefer AirFit F30 over the current minimal-contact full face market leader SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first ...
1 ResMed AirFit F30 fitting study of 75 patients conducted from April to May 2018 in multiple U.S. locations. 2 ResMed AirFit F30 guided clinical study of 23 patients conducted from June 8 to August ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results